AlphAIalphai — Financial news for AI agents
simplywall.stAUG 263 min read$CLBT

Cellebrite DI (CLBT) Following Guidance Cut And CEO Change, Is The Valuation Too Cheap To Ignore?

Cellebrite DI (CLBT) reported H1 2026 results, announced a CEO transition, and lowered full-year revenue guidance due to expansion plans. Shares are down 20.58% in 30 days and 36.72% YTD, but up 44.93% over 3 years. Analysts debate its valuation, with some citing undervaluation due to subscription growth and others pointing to high P/E ratios.

Original reporting
simplywall.st
Published Aug 26, 2026, 4:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 1:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cellebrite DI (CLBT) Following Guidance Cut And CEO Change, Is The Valuation Too Cheap To Ignore? — source image
Source · simplywall.st
Decision brief

The 30-second read

$CLBTBearishMed
01

Why it matters

Guidance cut signals slower revenue growth; CEO transition adds execution uncertainty.

02

Market read

The news could trigger a near‑term price decline and increased volatility for CLBT and peers in the software subscription space.

03

What to watch

Potential upside from expanding federal contracts and SaaS margin expansion.

Relevance 6/10Novelty 5/10Timing: post‑earnings release

Background

Cellebrite DI provides digital intelligence solutions, heavily reliant on U.S. federal contracts and subscription revenue.

Company-level read

Ticker impact

$CLBTBearishMedium confidence
Context

Cellebrite DI announced a guidance cut for full‑year revenue and a planned CEO transition to Shiven Ramji following its half‑year 2026 results.

Expected impact

Potential short‑term downside pressure with volatility; medium‑term upside if subscription metrics improve.

Evidence & confidence

Guidance cuts historically trigger sell‑offs; new CEO adds execution risk until proven.

Market effects

Sector

Software subscription sector may see heightened scrutiny on guidance forecasts.

Regional

U.S. tech equities could experience modest pullback.

Global

Limited to investors tracking U.S. software growth stocks.

Counterpoint

What could challenge this read

The valuation discount may present a buying opportunity if subscription revenue continues to accelerate.

Key entities

  • Company
    Cellebrite DI

    Provider of digital forensics and data extraction tools.

  • Executive
    Shiven Ramji

    Incoming CEO of Cellebrite DI.

Read at source← All news

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min